Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04592250 · ClinicalTrials.gov registry record

Financial Toxicity in Cancer Patients

A clinical trial of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
625
Enrollment target
6
Study locations

NCT04592250 is a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 625 participants, below the 1,137-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (45% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04592250, a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
625 participants
Enrollment target
6
Study locations

Study Summary

This study will seek to generate the early data needed to understand the relationship between constructs and measures of patients' coping resources and psychological response and measures of patients' financial toxicity. To collect this early descriptive data, the overall goal of this study is to identify social, behavioral, and knowledge factors associated with financial toxicity outcomes. Identifying these factors will ultimately help elucidate targets for behavioral, psychosocial, and/or educational and coaching interventions.

Conditions Studied

Malignant Solid Neoplasm Hematopoietic and Lymphoid Cell Neoplasm

Interventions

  • OTHER Survey Administration

Study Locations (6)

Texas

  • Lyndon Baines Johnson General Hospital - Houston
  • M D Anderson Cancer Center - Houston

Alabama

  • DCH Regional Medical Center - Tuscaloosa

California

  • Scripps - MD Anderson Cancer Center - La Jolla

Florida

  • Baptist- MD Anderson Cancer Center - Jacksonville

Hawaii

  • The Queen's Medical Center - Honolulu

Trial Details

FieldValue
Enrollment Target 625 participants
Start Date 2020-09-12
Est. Completion 2028-09-01

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04592250

The ClinicalTrials.gov registry entry for NCT04592250 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 625 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,137-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (45% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Survey Administration is the first listed.

NCT04592250 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT04592250 about?

NCT04592250 is a clinical study titled "Financial Toxicity in Cancer Patients". This study will seek to generate the early data needed to understand the relationship between constructs and measures of patients' coping resources and psychological response and measures of patients' financial toxicity. To collect this early descriptive data, the overall goal of this study is to id...

What is the current status of trial NCT04592250?

This trial is currently active not recruiting. The enrollment target is 625 participants. The study started on 2020-09-12. Estimated completion is 2028-09-01.

What conditions does trial NCT04592250 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm.

What interventions are being tested in trial NCT04592250?

The interventions under investigation include: Survey Administration (OTHER).

Who is sponsoring clinical trial NCT04592250?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04592250 being conducted?

This trial has 6 study locations across Alabama, California, Florida, Hawaii, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Malignant Solid Neoplasm

All registered trials for this condition

Hematopoietic and Lymphoid Cell Neoplasm

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.